Andere talen Formosa Pharmaceuticals, Inc.

Aandelen

6838

TW0006838006

slotkoers Taipei Exchange Andere beurzen 00:00:00 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
52,9 ^TWD	-1,12%		-3,64%	+5,91%

07/03	Formosa Pharmaceuticals, Inc. Kondigt FDA-goedkeuring aan voor de NDA van een wereldwijd innovatief hormoon Nanosuspensie Oogdruppels	CI
05/03	Eyenovia feliciteert Formosa Pharmaceuticals met de FDA-goedkeuring van clobetasol propionate Ophthalmic Suspension 0,05% voor de behandeling van postoperatieve ontsteking en pijn na oogchirurgie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops	07/03
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery	05/03
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery	05/03
US FDA approves Eyenovia's eye drug, Formosa Pharma says	05/03
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	26/01
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/12
Formosa Pharmaceuticals, Inc.(TPEX:6838) added to S&P Global BMI Index	18-09-23
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	11-08-23
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery	05-05-23
Grand Pharmaceutical Group's Eye Drops Show Safety in Phase 2, 3 Trials	12-04-23
Formosa Pharmaceuticals, Inc. Announces Phase III Clinical Study of a Global Innovative Hormone Nanosuspension Eye Drops Successfully Reached Clinical Endpoint	11-04-23
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21-03-23
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21-03-23
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics	15-02-23
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	11-08-22
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery	09-08-22
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery	12-05-22
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16-03-22
HCmed Innovations, Formosa Laboratories, and Formosa Pharmaceuticals Signs MoU to Form A Global CDMO for Inhalation Treatment Drugs	07-03-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Formosa Pharmaceuticals, Inc.

Aandelen

6838

TW0006838006

Andere talen

Filters